Cargando…

Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia

OBJECTIVES: The aim of this study was to evaluate the cost effectiveness of ambulatory blood pressure monitoring (ABPM) compared with home blood pressure monitoring (HBPM) and clinic blood pressure monitoring (CBPM) in diagnosing hypertension in Australia. METHODS: A cohort-based Markov model was bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shah, Karan K., Willson, Melina, Agresta, Blaise, Morton, Rachael L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929017/
https://www.ncbi.nlm.nih.gov/pubmed/36121638
http://dx.doi.org/10.1007/s41669-022-00364-0
_version_ 1784888756786954240
author Shah, Karan K.
Willson, Melina
Agresta, Blaise
Morton, Rachael L.
author_facet Shah, Karan K.
Willson, Melina
Agresta, Blaise
Morton, Rachael L.
author_sort Shah, Karan K.
collection PubMed
description OBJECTIVES: The aim of this study was to evaluate the cost effectiveness of ambulatory blood pressure monitoring (ABPM) compared with home blood pressure monitoring (HBPM) and clinic blood pressure monitoring (CBPM) in diagnosing hypertension in Australia. METHODS: A cohort-based Markov model was built from the Payer’s perspective (Australian government) comparing lifetime costs and effectiveness of ABPM, HBPM and CBPM in people aged ≥ 35 years with suspected hypertension who have a CBPM between ≥ 140/90 mmHg and ≤ 180/110 mmHg using a sphygmomanometer and have not yet commenced antihypertensive treatment. The main outcome measures were incremental cost-effectiveness ratio (ICER) assessing cost per quality-adjusted life-year (QALY) and life-years (LYs) gained by ABPM versus HBPM and CBPM. Cost was measured in Australian dollars (A$). RESULTS: Over a lifetime model, ABPM had lower total costs (A$8,491) compared with HBPM (A$9,648) and CBPM (A$10,206) per person. ABPM was associated with a small but significant improvement in the quality and quantity of life for people with suspected hypertension with 12.872 QALYs and 17.449 LYs compared with 12.857 QALYs and 17.433 LYs with HBPM, and 12.850 QALYs and 17.425 LYs with CBPM. In the base-case analysis, ABPM dominated HBPM and CBPM. In scenario analyses, at 100% specificity of HBPM, ABPM no longer remained cost effective at a A$50,000/QALY threshold. However, in probabilistic sensitivity analysis, over 10,000 iterations, ABPM remained dominant. CONCLUSION: ABPM was the dominant strategy for confirming the diagnosis of hypertension among Australian adults aged ≥ 35 years old with suspected hypertension. The findings of this study are important for reimbursement decision makers to support policy change and for clinicians to make practice changes consistent with ABPM recommendations in primary care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00364-0.
format Online
Article
Text
id pubmed-9929017
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-99290172023-02-16 Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia Shah, Karan K. Willson, Melina Agresta, Blaise Morton, Rachael L. Pharmacoecon Open Original Research Article OBJECTIVES: The aim of this study was to evaluate the cost effectiveness of ambulatory blood pressure monitoring (ABPM) compared with home blood pressure monitoring (HBPM) and clinic blood pressure monitoring (CBPM) in diagnosing hypertension in Australia. METHODS: A cohort-based Markov model was built from the Payer’s perspective (Australian government) comparing lifetime costs and effectiveness of ABPM, HBPM and CBPM in people aged ≥ 35 years with suspected hypertension who have a CBPM between ≥ 140/90 mmHg and ≤ 180/110 mmHg using a sphygmomanometer and have not yet commenced antihypertensive treatment. The main outcome measures were incremental cost-effectiveness ratio (ICER) assessing cost per quality-adjusted life-year (QALY) and life-years (LYs) gained by ABPM versus HBPM and CBPM. Cost was measured in Australian dollars (A$). RESULTS: Over a lifetime model, ABPM had lower total costs (A$8,491) compared with HBPM (A$9,648) and CBPM (A$10,206) per person. ABPM was associated with a small but significant improvement in the quality and quantity of life for people with suspected hypertension with 12.872 QALYs and 17.449 LYs compared with 12.857 QALYs and 17.433 LYs with HBPM, and 12.850 QALYs and 17.425 LYs with CBPM. In the base-case analysis, ABPM dominated HBPM and CBPM. In scenario analyses, at 100% specificity of HBPM, ABPM no longer remained cost effective at a A$50,000/QALY threshold. However, in probabilistic sensitivity analysis, over 10,000 iterations, ABPM remained dominant. CONCLUSION: ABPM was the dominant strategy for confirming the diagnosis of hypertension among Australian adults aged ≥ 35 years old with suspected hypertension. The findings of this study are important for reimbursement decision makers to support policy change and for clinicians to make practice changes consistent with ABPM recommendations in primary care. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s41669-022-00364-0. Springer International Publishing 2022-09-19 /pmc/articles/PMC9929017/ /pubmed/36121638 http://dx.doi.org/10.1007/s41669-022-00364-0 Text en © The Author(s) 2022, corrected publication 2022 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Original Research Article
Shah, Karan K.
Willson, Melina
Agresta, Blaise
Morton, Rachael L.
Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
title Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
title_full Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
title_fullStr Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
title_full_unstemmed Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
title_short Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
title_sort cost effectiveness of ambulatory blood pressure monitoring compared with home or clinic blood pressure monitoring for diagnosing hypertension in australia
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9929017/
https://www.ncbi.nlm.nih.gov/pubmed/36121638
http://dx.doi.org/10.1007/s41669-022-00364-0
work_keys_str_mv AT shahkarank costeffectivenessofambulatorybloodpressuremonitoringcomparedwithhomeorclinicbloodpressuremonitoringfordiagnosinghypertensioninaustralia
AT willsonmelina costeffectivenessofambulatorybloodpressuremonitoringcomparedwithhomeorclinicbloodpressuremonitoringfordiagnosinghypertensioninaustralia
AT agrestablaise costeffectivenessofambulatorybloodpressuremonitoringcomparedwithhomeorclinicbloodpressuremonitoringfordiagnosinghypertensioninaustralia
AT mortonrachaell costeffectivenessofambulatorybloodpressuremonitoringcomparedwithhomeorclinicbloodpressuremonitoringfordiagnosinghypertensioninaustralia